Home Cart Sign in  
Chemical Structure| 177355-84-9 Chemical Structure| 177355-84-9

Structure of DBeQ
CAS No.: 177355-84-9

Chemical Structure| 177355-84-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

DBeQ is a selective, potent, reversible, and ATP-competitive p97 inhibitor with IC50 of 1.5 μM.

Synonyms: JRF 12; N,N'-Dibenzylquinazoline-2,4-diamine

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of DBeQ

CAS No. :177355-84-9
Formula : C22H20N4
M.W : 340.42
SMILES Code : C1(NCC2=CC=CC=C2)=NC(NCC3=CC=CC=C3)=C4C=CC=CC4=N1
Synonyms :
JRF 12; N,N'-Dibenzylquinazoline-2,4-diamine
MDL No. :MFCD03691820
InChI Key :QAIMUUJJAJBPCL-UHFFFAOYSA-N
Pubchem ID :676352

Safety of DBeQ

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of DBeQ

DNA

Isoform Comparison

Biological Activity

Target
  • p97

    p97, IC50:1.5 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
Escherichia coli DnaK 100μM Binds to DnaK without affecting its ATPase activity PMC7948422
Escherichia coli ClpB 45μM Inhibits the ATPase activity of ClpB PMC7948422
HeLa cells 10 μM 3 h Evaluate the effect of DBeQ on the autophagy pathway, observed accumulation of LC3-II PMC3064330
Hek293 cells 10 μM 2 h Evaluate the effect of DBeQ on the ERAD pathway, observed accumulation of TCRα-GFP PMC3064330
OVCAR8 3 μM 48 h To study the synergistic effect of DBeQ and Salubrinal on OVCAR8 cells, results showed that the combination enhances cytotoxicity. PMC5423134
OVCAR5 4.5 ± 1.3 μM 72 h To evaluate the cytotoxic effect of DBeQ on OVCAR5 cells, results showed that DBeQ is cytotoxic to OVCAR5 cells. PMC5423134
SKOV3 10 μM 48 h To study the apoptotic effect of DBeQ on SKOV3 cells, results showed that DBeQ induces apoptosis through caspase-3 activation. PMC5423134
OVCAR10 2.5 ± 0.62 μM 72 h To evaluate the cytotoxic effect of DBeQ on ovarian cancer cell lines, results showed that DBeQ is cytotoxic to ovarian cancer cells. PMC5423134
RPMI8226 cells 10 μM 48 h Evaluate the inhibitory effect of DBeQ on cancer cell growth, observed significant growth inhibition PMC3064330

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice LPS-induced lung damage model Intraperitoneal injection 20 mg/kg Once daily for 7 days DBeQ treatment significantly decreased the generation of p52 PMC4528123

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.94mL

0.59mL

0.29mL

14.69mL

2.94mL

1.47mL

29.38mL

5.88mL

2.94mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories